Trial Profile
A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATLANTIC
- Sponsors AstraZeneca
- 11 Oct 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 15 Dec 2022 This trial has been completed in Germany according to European Clinical Trials Database record.
- 04 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.